21.04.21
MONTREAL, April 21, 2021 – ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, and Ossium Health, a therapeutics company harnessing the power of stem cell…
Read more
07.01.21
MONTRÉAL, January 7, 2021 – ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the publication of new data describing the mechanism of action of UM171,…
Read more
11.12.20
MONTRÉAL, December 11, 2020 – ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that ECT-001 Cell Therapy has been granted PRIority MEdicines (PRIME) designation by…
Read more
20.10.20
MONTRÉAL, October 20, 2020 – ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has received Advanced Therapy Medicinal Product (ATMP) classification from the…
Read more
18.08.20
MONTREAL, August 18, 2020 – ExCellThera Inc., a clinical stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that additional data from a Phase I/II clinical trial…
Read more
15.07.20
MONTREAL, July 15, 2020 – ExCellThera Inc., a clinical stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the appointment of Richard Cherney to its Board of…
Read more
03.06.20
MONTRÉAL, JUNE 3, 2020 – ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today new appointments to its Board of Directors and Scientific Advisory…
Read more
19.05.20
MONTRÉAL, May 19, 2020 – ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has received a grant from the California Institute for Regenerative…
Read more
30.04.20
MONTREAL, April 30, 2020 — ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the European Medicines Agency has granted orphan medicinal product designation as…
Read more
25.02.20
MONTREAL, February 25, 2020 – ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, recently announced preliminary data from the Phase 2 trial of its ECT-001 Cell Therapy…
Read more
26.11.19
MONTRÉAL, November 26, 2019 – ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that data from a Phase I/II clinical trial using its lead technology, ECT-001,…
Read more
05.11.19
MONTRÉAL, November 5, 2019 – ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the publication of full data from the first clinical trial using ECT-001 (single…
Read more
11.09.19
MONTREAL, September 11, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that Guy Sauvageau, President and CEO, will present a company update…
Read more
23.04.19
MONTREAL, April 23, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative…
Read more
25.03.19
MONTREAL, March 25, 2019 – ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that its lead technology, ECT-001, will be used as part of two…
Read more
17.12.18
MONTREAL, December 17, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted the ExCellThera’s lead solution,…
Read more
04.12.18
MONTREAL, December 4, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced results from the Phase I/II clinical trial using its lead technology, ECT-001, for allogeneic…
Read more
08.11.18
MONTREAL, November 8, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced that results from the Phase I/II clinical trial using its lead technology, ECT-001, for…
Read more
27.06.18
MONTREAL, June 27, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced today the close of its initial, 25-patient clinical trial for its lead technology, ECT-001. The final…
Read more
14.05.20
(le français suit) MONTREAL, May 14, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced today that its lead platform, ECT-001, will be used as part of a…
Read more
22.03.18
(le français suit) MONTREAL, March 22, 2018 – ExCellThera Inc. announced today the appointment of David Millette as Chief Financial and Legal Officer effective April 3, 2018. Mr. Millette combines a solid background in finance and law, having practised in…
Read more
Subscribe